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Introduction 6	
Glioblastoma (previously called glioblastoma multiforme, GBM) is the most common 7	
malignant primary brain tumour in adults. Despite multimodality treatment comprising 8	
maximal safe resection, radiotherapy and concomitant (chemo-RT) and adjuvant 9	
chemotherapy, the best median survival is in the range of 14-18 months.1,2 Efficacy of 10	
therapy may be evaluated by patient survival, though image-based criteria to evaluate 11	
disease response exist. Macdonald et al.3 developed criteria for assessing the response of 12	
supratentorial GBM based on the area of contrast enhancement (CE) on computed 13	
tomography (CT), subsequently adapted for MRI, in conjunction with clinical assessment and 14	
steroid use.  15	
By the Macdonald criteria, progressive disease is determined by a 25% or greater increase 16	
in the product of the perpendicular diameters of the largest area of contrast enhancement. 17	
Increasingly, transient treatment-related changes on imaging mimicking progressive disease 18	
are being recognised. An increase in the enhancing area on MRI can be induced by a 19	
variety of nontumoural processes such as post-surgical changes, radiation effects and 20	
ischaemia4,5. These “pseudoprogression” cases, which are generally not associated with 21	
clinical deterioration, stabilize or resolve without any change in treatment (figure 1).  22	
Figure 1 23	
Pseudoprogression has been observed in multiple studies and is estimated to occur in about 24	
20% of patients following GBM treatment.6–10 In a large study by Taal et al.11 50% of patients 25	
treated with chemoRT for GBM with worsening MRI features on early MRI actually showed 26	
stabilization or resolution of those MRI features without any change in treatment.  Wrongly 27	
diagnosing pseudoprogression as true tumour progression on gadolinium-enhanced MRI 28	
could lead to an inappropriate change in therapy and errors in assessing the efficacy of 29	
novel treatments. This was addressed in the updated response assessment criteria 30	
developed by the Response Assessment in Neuro-Oncology Working Group (RANO) which 31	
suggests that in the first 12 weeks after therapy, when pseudoprogression is more prevalent, 32	
progression can only be diagnosed if there is new enhancement outside the radiation field 33	
(image 1).12 More advanced MRI techniques and molecular imaging are showing promise in 34	
differentiating responders to treatment from non-responders at an early stage and will allow 35	
more judicious treatment administration and early termination of ineffective treatment plans. 36	
Table 1. RANO criteria for high-grade gliomas 37	
The purpose of this review is to outline the current research into radiological assessment of 38	
GBMs, specifically the differentiation between pseudoprogression and true tumour 39	
progression. 40	
It should be noted that pseudoprogression and radiation necrosis (late-delayed radiation 41	
effects) are not interchangeable terms.14 Pseudoprogression typically occurs earlier (within 6 42	
months of chemo-RT) and the histopathology is not completely understood.15 For the 43	
purpose of this review studies that include patients with apparent progression on imaging 44	
occurring within six months of treatment have been categorised as pseudoprogression. 45	
Literature search 46	
A broad search was conducted between April 2014 to November 2014 on PubMed (National 47	
Library of Medicine, http://www.ncbi.nlm.nih.gov) using “ALL FIELDS” and entering 48	
“GLIOBLASTOMA” AND “PSEUDOPROGRESSION”. Abstracts were hand searched and 49	
those that were not on topic excluded. Electronic copies of the relevant studies were 50	
accessed via secure access to the hospital library.  51	
The exclusion criteria applied included laboratory only studies; non-human studies; non-52	
english language studies; paediatric population; and newly diagnosed glioblastoma patients.  53	
Overall, 69 publications met the criteria. These included five focusing on conventional MRI; 54	
16 on diffusion weighted MRI (DWI); 13 on perfusion MRI; 13 on MR spectroscopy (MRS); 55	
18 on positron emission tomography (PET); 12 on single photon emission computed 56	
tomography (SPECT); and eight on serial studies and multimodality imaging. 57	
Imaging techniques  58	
Conventional MRI 59	
Tissue signal intensity appearances on T2-weighted MRI (T2W) and T1-weighted 60	
gadolinium-enhanced MRI (T1WGd) do not reliably distinguish pseudoprogression from 61	
tumour progression as both can show new enhancement on T1WGd next to the resection 62	
cavity and progressive enlargement with mass effect.4,16 Some distinguishing features of 63	
tumour progression include corpus callosum involvement, subependymal spread, and 64	
multiple lesions.17 A larger 3D volume has been used to predict a worse prognosis.18  65	
In a more recent study the MRI scans of 321 patients were retrospectively analysed based 66	
on 11 MRI signs.19 Only subependymal enhancement (figure 2) was predictive for true 67	
tumour progression (p = 0.001) with 93.3% specificity, though the sensitivity and negative 68	
predictive values were only 38.1% and 41.8% respectively. The poor predictive value of 69	
subependymal enhancement is reflected in the earlier retrospective study of Kumar et al.4 70	
which found that radiation necrosis showed a predilection for the periventricular white matter 71	
within the radiation portal. They found that a “Swiss cheese” enhancement pattern more 72	
frequently showed radiation necrosis on histopathology.  73	
Figure 2 74	
Conventional MRI is, therefore, inadequate for differentiating tumour progression from 75	
pseudoprogression except in the situation in which new enhancement occurs outside the 76	
radiation field.20  77	
Diffusion-weighted MRI 78	
The signal created in DWI depends upon the self-diffusion of tissue water. The presence of 79	
cell walls and other tissue structures restricts water diffusion leading to increases in the DWI 80	
signal. However, the DWI signal is a complex function of many parameters and high signal 81	
can also be caused by elevated T2 values (the T2 shine-through artefact). If is therefore 82	
usual to calculate an apparent diffusion coefficient (ADC) map from the DWI signal. Low 83	
ADC values unambiguously identify restricted diffusion of water molecules caused by 84	
increased cellularity or changes in the cytoarchitecture of cells in tumours.  85	
GBMs are highly cellular structures causing restricted diffusion of water. Diffusion signal 86	
characteristics are already being used to diagnose and grade cerebral gliomas.21–23 87	
Hein et al.24 investigated the use of DWI in differentiating pseudoprogression from tumour 88	
progression. ADC maps were obtained starting one month after the treatment of GBM in 89	
patients with newly enhancing lesions. MRI Recurrence was established by clinical course or 90	
histological examination in combination with imaging studies. The mean ADC value of newly 91	
enhancing lesions was significantly lower in the tumour progression group than in the 92	
pseudoprogression group (p < 0.006). ADC ratios (ADC of enhancing lesion to ADC of 93	
normal contralateral white matter) were also lower (p < 0.001).  94	
This result was repeated in other prospective studies showing that the maximal ADC values 95	
were significantly lower for the recurrence group than for the pseudoprogression groups 96	
(maximal ADC 2.30 ± 0.73 for radiation group and 1.68 ± 0.37 for tumour progression)25 and 97	
that the minimum ADC value was significantly lower in the recurrent tumour group than in 98	
the radiation-injuries group26 based upon non-progression on follow-up and histology. 99	
Limitations 100	
There are several limitations of DWI in post-treatment GBM due to spatial and temporal 101	
sampling errors.  102	
Like any quantitative measurement of a dynamically evolving pathological process like a 103	
GBM, ADC measurements will change over time so that obtaining a “characteristic” value at 104	
a single time point is not possible.  105	
Spatially there are three issues. Firstly, the ADC value measured will differ depending on the 106	
relative amounts of tumour, peritumoural oedema, and necrosis included in the sample. The 107	
area sampled is usually determined by regions of enhancement on T1WGd – which has a 108	
poor specificity for differentiating between different pathological features – and ADC has 109	
been shown to be poor in differentiating tumour from peritumoural oedema.21,27 Secondly, a 110	
potential pitfall is inter-observer variance in drawing the region of interest (ROI) and, 111	
therefore, measuring inconsistent ADC values.28 Finally, the diffusion anisotropy of different 112	
areas of normal brain varies considerably and care must be taken to compare the fractional 113	
anisotropy (FA) values of the ROI to an area as similar as possible in the contralateral 114	
hemisphere.29 115	
It should be noted that these limitations are not unique to DWI but are shared with most of 116	
the techniques described below. 117	
Susceptibility weighted imaging with DWI 118	
Susceptibility weighted imaging (SWI) is an alternative to T1WGd that may better identify 119	
areas suitable for ADC measurements. SWI is a 3D gradient echo technique that provides 120	
images that are sensitive to subtle variations in susceptibility caused by deoxyhaemoglobin. 121	
SWI has been shown to be more sensitive than T1WGd for showing the heterogeneity of 122	
tissue pathology in brain tumours.30–32 Also, gadolinium-enhanced SWI (SWI-Gd) can 123	
provide clinically useful information on altered tumour microvascularity and cellular density33; 124	
the degree of intratumoural necrosis34; and the presence of abnormal enhancement around 125	
the tumour post-contrast suggesting a breakdown in the blood-brain barrier.35  126	
Targeting areas for ADC analysis using SWI-Gd instead of T1WGd has shown promise.36 127	
ADC measurements taken from enhancing areas on SWI-Gd were significantly reduced in 128	
10 out of 11 patients with tumour recurrence. ADC values also fell over time. Conversely, 129	
ADC measures taken from enhancing areas on T1WGd were significantly reduced in only 130	
three of 11 patients and actually increased in four of 11 patients.  131	
In the same study, ADC measurements of enhancing areas on SWI-Gd were increased in 132	
four out of six patients with pseudoprogression and increased further over time. The findings 133	
are promising but more data is required to assess the validity of using SWI-Gd and DWI. 134	
Although identification of enhancing regions by SWI-Gd has only been applied to DWI 135	
measurements it could in principle be combined with any of the MRI methods described 136	
below and may thus improve their performance. 137	
Diffusion-tensor imaging 138	
Diffusion-tensor imaging (DTI) is an extension of DWI that samples water motion in at least 139	
six non-collinear directions to provide additional information about the direction of water 140	
motion. This data can then be used to compute maps of fractional anisotropy (FA) showing 141	
the preferential direction of water diffusion along white matter tracks as well as computing 142	
the ADC map. Confusingly, ADC is usually called mean diffusivity (MD) in the DTI literature 143	
but the two are essentially identical. Since the direction of diffusion is largely determined by 144	
the presence of white matter tracts DTI provides a sensitive means of detecting alterations in 145	
the integrity of white matter structures and hence a means of detecting infiltrating tumour.  146	
In a prospective study the mean ADC ratio in new enhancing areas on T1WGd was 147	
significantly lower and the mean FA ratio significantly higher in patients with tumour 148	
recurrence compared to those with pseudoprogression.37 Neither the mean ADC ratio nor 149	
the FA ratio in the areas of oedema showed any significant difference. They suggested that 150	
an ADC ratio of less than 1.65 or an FA ratio greater than 0.36 in the enhancing lesion 151	
suggested tumour recurrence. However, with this cutoff three patients with recurrent tumour 152	
and two with radiation injury were misclassified.  153	
A later study supported these findings.38  An ADC ratio cut-off value of 1.27 could 154	
differentiate recurrence from treatment-induced necrosis with 65% sensitivity and 100% 155	
specificity. However, DTI was found to be inferior to both dynamic susceptibility contrast MRI 156	
and brain SPECT in differentiating tumour recurrence from necrosis.  157	
ADC ratios may also be useful in assessing perilesional oedema as it has been shown to 158	
differentiate recurrent tumour from pseudoprogression.39 159	
Limitations 160	
The low sensitivity of DTI means that it is not an ideal method for assessing recurrence post-161	
treatment. One area it may be useful in is in predicting the pattern of glioma recurrence.40 162	
Also, the cutoff values proposed by authors have differed which may be due to different MRI 163	
sequence protocols and equipment.   164	
Perfusion MRI 165	
The most common perfusion MRI technique to assess glioma is T2* echo-planar dynamic 166	
susceptibility contrast imaging (DSC-MRI). DSC-MRI provides estimates of absolute cerebral 167	
blood flow (CBF), cerebral blood volume (CBV), and relative CBV (rCBV). Radiation necrosis 168	
is typically a diffuse process with fibrinoid necrosis of small vessels, endothelial thickening 169	
and hyalinization, and vascular thrombosis leading to reduction of perfusion to the brain. By 170	
contrast, active glioma growth is tightly coupled with angiogenesis leading to increased 171	
perfusion. DSC-MRI could therefore provide a valuable means of differentiating the two 172	
based on the vascularity of the imaged areas (figure 3)41. 173	
Figure 3  174	
Pre-operative DSC-MRI images were obtained of 13 patients with new enhancing lesions on 175	
MRI following treatment for GBM and in whom further resection was planned.42 The rCBV 176	
values of the biopsied sites were compared with the histopathology by recording stereotactic 177	
biopsy locations and co-registering these to the perfusion images. rCBV values higher than 178	
0.71 indicated tumour progression with a sensitivity of 91.7% and a specificity of 100%. 179	
However, co-registration is imperfect due to brain movement during biopsy and DSC-MRI 180	
images are of low resolution. This has been supported by other studies that found a higher 181	
rCBV in patients with recurrent tumour than in patients with radiation necrosis. However, 182	
patients received only dendritic cell immune therapy and surgery43 or external beam 183	
radiotherapy44. A study also found a negative correlation between rCBV and median 184	
survival.45 185	
The percentage change in rCBV one month following treatment was found to be the variable 186	
that had the most significant correlation with median survival.46 Those with an increase in 187	
rCBV had a significantly lower median survival than those with a decrease in rCBV.  188	
Determination of the O-6-methylguanin-DNA methyltransferase (MGMT) status of patients 189	
may be necessary for accurate interpretation of the significant difference between 190	
pseudoprogression and true progression. GBMs that show methylation of the MGMT gene 191	
promoter have been associated with an improved response to chemotherapeutics.47 The 192	
significance was greater in patients with unmethylated MGMT than in those with 193	
hypermethylated MGMT (p = 0.003)31 and not significant at all in patients with methylated 194	
MGMT (p = 0.258).48  195	
An alternative technique, dynamic contrast enhanced (DCE) T1-weighted perfusion MRI has 196	
not been as commonly investigated as DSC-MRI. Analysis of the mean area under the curve 197	
(AUC) of signal-intensity over time histograms (calculated as the initial AUC (at 0-30 198	
seconds) divided by the final AUC (at 320-250 seconds)) using DCE-MRI showed a 199	
significant difference between pseudoprogression and true progression (p = <0.001).49  200	
Limitations  201	
The imaging resolution of perfusion MRI studies is low making small areas of enhancement 202	
more difficult to assess. Analysis alongside high-resolution T1-weighted (T1W) or T2W 203	
imaging may help to alleviate this although partial volume effects are likely to remain. DSC-204	
MRI is also degraded by susceptibility artefacts making imaging of the posterior fossa less 205	
reliable.  206	
Spatially, care needs to be taken when using DSC-MRI to analyse tumours. Many lesions 207	
post-treatment are often intermingled tumour and necrotic tissue. rCBV may incorrectly 208	
estimate the lesion size due to contrast leak into necrotic tissue, a phenomenon which is 209	
discussed later. Also, the rCBV in the normal cortex is higher than in white matter.50 Different 210	
proportions of grey and white matter influence rCBV values independently of underlying 211	
pathology. 212	
Contrast Leak 213	
Because of the small molecular size of gadolinium (Gd), it rapidly crosses defects in the 214	
blood brain barrier (BBB). The BBB is frequently disrupted after chemoradiotherapy, as well 215	
as by the angiogenesis incited by tumours. Thus, gadolinium is rapidly cleared from the 216	
circulation. This leads to a contrast leak causing a reduction in T1. However, DSC-MRI 217	
calculations of CBV and CBF are only accurate if T1 remains unchanged. Several methods 218	
have been proposed to overcome this problem.51 For example, a software leak correction to 219	
values has been found to result in more accurate grading of gliomas.52 Alternatively, a 220	
contrast agent with a larger molecular size that does not readily cross a disrupted BBB can 221	
be used. Several groups have investigated ferumoxytol, an iron oxide nanoparticle with a 222	
modified carbohydrate coating that has a longer half-life and remains in the intravascular 223	
space longer than Gd. A pilot study found lesions that enhance on T1WGd and have low 224	
rCBV on ferumoxytol-DSC-MRI are more likely to represent pseudoprogression.53 225	
Gahramanov et al.54 found that ferumoxytol-based measurements of rCBV measurements 226	
that correlate better with median survival than leak corrected Gd-based measurements.  227	
Ferumoxytol also allows the use of steady-state imaging methods which can produce high 228	
resolution and distortion free maps of CBV.55  229	
In conclusion, perfusion MRI has the potential to be a very useful adjunct in assessing post-230	
treatment gliomas. However, optimum cutoff rCBV values reported in the literature vary 231	
widely and require further study.14 Similarly, the use of software leak correction and 232	
alternative intravascular contrast agents needs to be investigated further.  233	
MR spectroscopy 234	
MRS can identify various metabolic compounds in the imaged tissue including choline (Cho), 235	
creatin (cr), N-acetylaspartate (NAA) lactate, and lipids.  Although absolute quantification of 236	
metabolite concentrations is possible, it is normal to express measurements at the ratio of 237	
the metabolite signal to that of creatine, since the latter is largely unchanged with disease. 238	
Tumours demonstrate high Cho/Cr ratios due to an increased number of cells and increased 239	
synthesis of cell membranes, and low NAA/Cr ratios due to neuronal loss or damage. 240	
Necrotic tissue shows elevated lactate, a marker for anaerobic glycolysis, and elevated lipids 241	
in keeping with cell membrane degradation. MRS can be potentially used to distinguish 242	
tumour progression from radiation injury since the former will demonstrate higher Cho/Cr 243	
ratios and lower NAA/Cr ratios.56  244	
Single-voxel MRS used in early studies found significant differences in the Cho/Cr and 245	
NAA/Cr ratios between neoplastic, non-neoplastic lesions and contralateral normal brain.57 246	
However, single-voxel MRS proved problematic as lesions are often heterogeneous and 247	
sampling results in partial voluming and cross-contamination of metabolic ratios.58 Some 248	
studies suffered from a small sample size and being non-blinded.59–61  249	
Figure 4 250	
Figure 5 251	
Multivoxel spectroscopic imaging – 2D or 3D chemical shift imaging (CSI-MRS) – is now 252	
commonplace and enables coverage of a larger volume as well as investigation of multiple 253	
regions of the lesion and surrounding tissue, although voxels are still large.  Using 2D CSI-254	
MRS an elevated Cho/NAA ratio62 and NAA/Cr ratio63 have been found to correlate with 255	
recurrent tumour (figure 4 and 5)64. There is also the potential of applying cutoff values to 256	
assist in diagnosis as in a retrospective study of 29 patients (24 of whom had GBM) 2D CSI-257	
MRS which was used to assess areas of new enhancement at the site of previously treated 258	
brain neoplasm.56 A cut-off value of 1.8 for both Cho/Cr and Cho/NAA ratios correctly 259	
categorised 27 out of 28 patients as either recurrent/residual tumour or radiation injury. A 260	
similar study found that a Cho/Cr value greater than 1.79 gives a sevenfold increased 261	
likelihood of being pure tumour than pure necrosis.65 Using 3D-MRS gives slightly different 262	
cut-off values of 1.71 for both Cho/Cr and Cho/NAA ratios with a sensitivity of 94.1%, a 263	
specificity of 100%, and a diagnostic accuracy of 96.2%.66 Several studies support these 264	
findings but only included patients who had not received chemotherapy.67–69 265	
Limitations 266	
Potential pitfalls for the application of MRS are the susceptibility to artefact, especially for 267	
imaging the posterior fossa;56 low spatial resolution; the decreased specificity for 268	
heterogeneous tissue; and the difficulty in applying ratios universally due to the different MRI 269	
strengths, imaging protocols and algorithms used in different centres. 270	
Positron emission tomography imaging 271	
Theoretically, PET imaging should be useful in diagnosing tumour progression as these are 272	
metabolically active lesions with greater utilisation of glucose and, therefore, exhibiting 273	
greater uptake. However the application of PET in differentiating between tumour 274	
progression and pseudoprogression has not been straightforward. 275	
18F-labelled fluorodeoxyglucose (18F FDG-PET) is the most commonly used. Early studies 276	
into the use of 18F FDG-PET for differentiating between tumour progression and 277	
pseudoprogression were promising but suffered from very small samples, limited correlation 278	
with pathology, and only investigating patients who had been treated with radiation with or 279	
without surgery and with no concomitant chemotherapy.70–72  280	
Although a pilot study73 and an early study74 supported the use of 18F FDG-PET subsequent 281	
studies have shown that the sensitivity and specificity rates are too low to be clinically useful.  282	
A retrospective study of 31 patients correlated PET appearance with histological diagnosis.  283	
Histologically, 22 patients had tumour recurrence, eight radiation necrosis and one gliosis. 284	
16 patients with recurrence and seven patients with radiation necrosis had hypermetabolic 285	
PET scan. This study misidentified a large number of lesions as tumour progression (nine 286	
out of 30, 29%) due to radiation necrosis being of unexpectedly high FDG uptake.75   287	
There are also issues particular to imaging of the brain that makes FDG-PET problematic in 288	
assessing post-treatment gliomas. Firstly, subclinical seizure activity may increase uptake 289	
temporarily and mimic a hypermetabolic lesion.76 Secondly, tracer uptake is compared to the 290	
contralateral hemisphere, which is used as a control, but in whole brain irradiation the 291	
contralateral brain may demonstrate post-radiation changes in uptake. Thirdly, the brain, 292	
especially grey matter, has high background glucose metabolism making subtle focal 293	
increases in uptake difficult to see.  294	
Glucose loading has been used to better distinguish between tumour and brain tissue but 295	
this method is complicated by the need for constant glucose monitoring.77 Alternatively, 296	
delayed FDG-PET scanning, in which scanning takes place 180-480 mins after isotope 297	
injection, resulted in better delineation of the high uptake of cerebral tumours relative to grey 298	
matter, whole brain, or white matter.78  In this study, however, a range of pre- and post-299	
treatment gliomas of different grades were included. Also, the ability to differentiate between 300	
tumour progression and pseudoprogression was not addressed.  301	
Amino Acid Biomarkers 302	
Novel radiolabelled amino acid biomarkers are currently being investigated as a means of 303	
improving tumour identification by PET. These include 11C-methionine (C-Met), O-(2-304	
[18F]fluoroethyl)-L-tyrosine (18F-FET) and 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine 305	
(18F-FDOPA). These show a lower uptake in normal brain tissue in comparison to 18F-306	
FDG-PET. 307	
Most research has been conducted using 11C-Met-PET (figure 6)79. This biomarker has 308	
been found to show increased uptake in a range of cerebral malignancies when compared to 309	
benign lesions (including radiation necrosis) with a sensitivity of 92% and a specificity of 310	
100%.80 It has also been shown to be more sensitive than 18F-FDG-PET.81 However, 311	
studies into whether 11C-Met-PET is useful for differentiating between tumour progression 312	
and pseudoprogression have been contradictory or suffered from a small patient sample.82 A 313	
study of 26 patients with glioma found that although the standardised uptake values for 314	
recurrent tumour was higher than for necrosis, the sensitivity and specificity were only 315	
75%.83 However, metastatic brain tumours and gliomas were included in the study and 316	
patients had been treated with radiotherapy but not concomitant chemotherapy or surgery. A 317	
more recent and larger study found 11C-Met-PET to be superior to 18F-FDG-PET in 318	
diagnosing tumour progression versus pseudoprogression with a sensitivity of 95% and a 319	
specificity of 89% but, it was found to be inferior to DWI.84 A further study found no 320	
significant difference with 11C-MET-PET between recurrent tumour and 321	
pseudoprogression.85 322	
Figure 6 323	
A limiting factor is the short half-life of 11C-methionine requiring on-site cyclotron facilities 324	
and, therefore, limiting clinical use. 18F labelled aromatic amino acid analogues, including 325	
18F-FET and 18F-FDOPA, have now been developed which have a longer half-life. 326	
A study showed 18F-FET-PET had a sensitivity of 100% and specificity of 93% in diagnosing 327	
tumour progression in patients with subsequent clinical or histological confirmation.86 328	
Interestingly, these values were higher than for T2W, T1W and T1WGd MRI (sensitivity of 329	
50% and specificity of 94%). A subsequent prospective study with 18F-FET-PET and 330	
subsequent biopsy results available found a positive-predictive value of 84%.87 331	
18F-FDOPA is believed to rely on active transport mechanisms rather than, as in 332	
gadolinium-enhanced MRI, depending on BBB breakdown. In preliminary studies 18F-333	
FDOPA-PET has been shown have a greater contrast between tumour tissue and normal 334	
tissue than with 18F-FDG-PET and also  showed a sensitivity of 97% and specificity of 86% 335	
for true progression.88 The same group also investigated 18-F-FDOPA-PET/MRI fusion to 336	
improve resolution and localisation and proposed that FDOPA-PET may detect recurrence 337	
earlier than MRI and also better differentiate non-enhancing tumour from other causes of 338	
T2W signal change such as oedema.89 339	
Limitations 340	
In the studies on FDG-PET usage in post-treatment gliomas patients have been scanned at 341	
different intervals making correlation difficult. Although amino acid tracers are promising the 342	
degree of amino acid uptake in radiation necrosis is not well known and more research is 343	
needed to justify their use clinically. 344	
Single positron emission computed tomography 345	
SPECT is a 3D nuclear medicine technique. Thallium-201 (201Tl) has been shown to be 346	
useful in differentiating pseudoprogression from true progression with a sensitivity from 84% 347	
to 100% and a specificity from 50% to 100%.90–93 Yamamoto et al found a potential for 348	
cutoffs to be applied.93 The addition of 99mTechnetium-hexamethyl-propyleneamine oxime 349	
(99mTc-HMPOA) has been proposed as differentiating between pseudoprogression and true 350	
progression in intermediate cases.94 However, 201Tl has a low spatial resolution and a 351	
relatively high radiation dose. This also results in an insensitivity to small or thinly rim-352	
enhancing lesions.95 353	
99mTechnetium (99mTc) based radiotracers have a better photon flux resulting in greater 354	
spatial resolution and lower radiation doses. 99mTc-sestamibi is the most commonly used 355	
technetium-based tracer and has a sensitivity of 95% and a specificity of 60% in 356	
differentiating pseudoprogression from tumour progression in patients who had only received 357	
radiotherapy.96 However, unlike 201Tl, 99mTc shows uptake in normal tissues such as the 358	
choroid plexus. 359	
Other 99mTechnetium-based tracers have also been studied. 99mTc-tetrofosmin does not 360	
cross the BBB meaning there is no uptake in normal brain tissues and it shows greater 361	
uptake in tumour relative to the background than 201Tl.97 Similarly, 99mTc-glucoheptonate 362	
provided more information on recurrent tumour including the tumour margins, extent and 363	
intratumoural necrosis.98 364	
Limitations 365	
201Tl studies have a low spatial resolution and a relatively high radiation dose. Despite 366	
having a greater photon flux 99mTc-sestamibi radiotracer shows uptake in normal tissues of 367	
the choroid plexus and pituitary gland, which limits the sensitivity. It also has poor sensitivity 368	
for posterior fossa tumours. Although 99mTc-tetrofosmin does not cross the BBB and 99mTc-369	
glucoheptonate provides more information on the extent and intratumoural necrosis of 370	
recurrent tumour, the availability is limited and more studies are required to establish the 371	
sensitivity and specificity.97,98 372	
Sequential imaging and combination of techniques  373	
So far each technique has been assessed individually with imaging mainly at one point in 374	
time. In practice techniques are often combined and changes assessed over time to give a 375	
greater overview of pathology.  376	
Combining MRS with DWI99, perfusion MRI100 or both101 has been shown to improve the 377	
sensitivity and specificity of differentiating true progression from tumour progression. 378	
Similarly, combining 18F-FET-PET and MRS with conventional MRI increased the accuracy 379	
of detecting brain tumours from 68% to 97%.102 380	
Performing DSC-MRI before treatment and one month after treatment showed that in 381	
pseudoprogression there was a 41% mean decrease in rCBV whereas tumour progression 382	
showed a 12% increase in rCBV.46 This was supported by a later study.103  383	
ADC measurement decreased at follow-up with tumour progression but increased in those 384	
with pseudoprogression when performing DTI at two time-points after treatment.36 385	
A recent study that performed DWI and perfusion MRI at two time points after treatment 386	
found the analysis that gave the most accurate differentiation between pseudoprogression 387	
and tumour progression was the mode of the rCBV on a multiparametric subtracted 388	
histogram. This was created by combining the ADC and rCBV histograms then subtracting 389	
the histogram of the initial MRI from the follow-up MRI.104 390	
Limitations to imaging with multiple techniques over time are high cost, lengthy scan times 391	
and patients having to attend several appointments. Also, centres may not have access to 392	
certain imaging methods leading to patients having to travel for further scans.  393	
Summary 394	
Imaging Method Supporting 
Studies 
Pattern 
associated 
with 
progression 
Strengths Weaknesses 
Conventional MRI 
and T1WGd 
4,16–19 Subependymal 
spread 
Corpus 
callosum 
involvement 
Readily available Large overlap of 
features meaning 
inadequate 
differentiation of 
tumour recurrence 
from 
pseudoprogression  
Diffusion 
weighted MRI 
24–26,36,66 ADC ratio and 
mean ADC 
lower 
Readily available 
Assesses pathology at 
microscopic level 
Confounded by 
temporal and spatial 
variation 
Improved by using SWI 
to select appropriate 
enhancing area to 
sample 36 
Diffusion Tensor 
Imaging 
37–40 Mean ADC 
lower and 
mean FA ratio 
higher 
Potentially could apply 
cut-off values 
Inferior to DSC-MRI 
and brain SPECT 
Low sensitivity  
Perfusion MRI 
(DSC-MRI) 
31,42–46,48,51–
55 
Higher rCBV High rates of sensitivity 
and specificity 
Low resolution 
Prone to susceptibility 
artefacts 
Contrast leak – may be 
overcome by 
alternative contrast 
agent 53,54 
Perfusion MRI 
(DCE-MRI) 
49 Increase in 
area under 
curve 
histogram 
analysis  
Less susceptible to 
artefacts than DSC-
MRI 
Potentially could apply 
cut-off values 
Not commonly used 
technique 
Requires more 
research 
MR Spectroscopy 56–63,66–69 Higher Cho/Cr 
ratios and 
lower NAA/Cr 
ratios 
Potentially could apply 
cut-off values 
High sensitivity and 
specificity 
Susceptible to artefact 
Low spatial resolution 
Difficulty in imaging 
mixed tumour/necrotic 
tissue 
FDG-PET 
imaging 
70–75,77,78 Considerable 
overlap 
Readily available High background 
signal – could be 
improved by delayed 
imaging 
Unacceptably low 
sensitivity and 
specificity 
C-Met-PET 80,82–85 Higher SUV  Lower background 
activity than FDG-PET 
Short half-life limits 
availability 
FET-PET and 
FDOPA-PET 
86–89 Higher SUV Could give higher 
sensitivity and 
Still in early research 
stages 
specificity than 
conventional MRI 
Greater contrast 
between tumour and 
normal brain tissue 
SPECT 90–94,96–98 Higher SUV 99mTc-glucoheptonate 
and 99mTc-tetrofosmin 
show high sensitivity 
and specificity 
99mTc-sestamibi 
crosses the BBB and is 
poor for posterior fossa 
tumours 
Limited availability of 
99mTc-glucoheptonate 
and 99mTc-tetrofosmin 
 395	
Discussion 396	
Currently the criteria for assessing tumour progression after GBM treatment is based upon 397	
an increase in the 2D area of contrast enhancement. However, up to 20% of patients may 398	
show transient sub-acute reactions usually within 6 months of treatment that mimic 399	
progression.6–10,15 Distinguishing tumour progression from pseudoprogression is important in 400	
the ongoing management of patients after treatment of GBMs and in accurately investigating 401	
treatment response in clinical trials. Both have overlapping features on radiology that make 402	
differentiation difficult. In this review the current literature on the use of different imaging 403	
modalities and their limitations has been outlined. Conventional T2W, T1W and T1WGd MRI 404	
has been shown to be inadequate in correctly differentiating true progression from 405	
pseudoprogression but more advanced MRI sequences, as well as molecular imaging, are 406	
proving promising.  407	
No single technique is able to reliably differentiate between pseudoprogression and tumour 408	
progression and in practice a combination of different modalities and comparison of images 409	
over time may prove more useful. Anatomical imaging (conventional MRI), imaging of 410	
histological properties of tissue (DWI, SWI, DTI and MRS) and imaging of functional 411	
properties of tissue (perfusion MRI and PET) may be combined to provide a more complete 412	
assessment of post-treatment gliomas. The comparison of follow-up images over time also 413	
provides valuable information. Further investigation is required into the individual techniques 414	
and into combinations of techniques to provide a more robust framework for clinicians and 415	
radiologists in the evaluation of post-treatment gliomas. 416	
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Figure Legends 705	
Figure 1.  706	
A patient with GBM with a a) post-surgical MRI showing progression on MRI at b) 1 months 707	
and c) 4 months post-radiotherapy. However, there was subsequent stabilisation at c) 7 708	
months post-radiotherapy indicating pseudoprogression.  709	
Figure 2.  710	
The images are of a patient with recurrent GBM, as proven by clinical deterioration, at two 711	
time-points after treatment. Images show early subependymal enhancement 1 month after 712	
treatment on the T1WGd 1A) coronal and 1B) axial images with further subependymal 713	
enhancement at 4 months after treatment on the T1WGd 2A) coronal and 2B) axial images.  714	
Figure 3. 715	
Glioblastoma multiforme in a 65-year-old woman. Axial T2-weighted (a) and T1-weighted 716	
post contrast (b) images demonstrate a right temporal lesion with surrounding edema and 717	
ring-shaped enhancement. On the DW-image the lesion presents low signal 718	
intensity(c) resulting in higher intratumoral ADC (d), lower intratumoral FA (e), and high 719	
peritumoral rCBV (f), reflecting tumor infiltration in the surrounding parenchyma. Reproduced 720	
from Cancer Imaging, Biomed Central Ltd. 721	
Figure 4. 722	
Radiation injury in a 46-year-old man who underwent surgery, radiotherapy, and 723	
chemotherapy for a left insular lobe glioblastoma multiforme (N-acetylaspartate, NAA; 724	
choline-containing compounds, Cho; creatine, Cr). (A) The first contrast-enhanced axial T1-725	
weighted image which volume of interest for MR spectroscopy is placed on. (B) 3D proton 726	
MR spectroscopy of contrast-enhancing region which shows pathologic spectra (Cho/NAA, 727	
1.35; Cho/Cr, 1.63; NAA/Cr, 1.21). (C) The contrast-enhanced T1-weighted image at 15-728	
month follow-up after 3D proton MR spectroscopy which reveals marked regression of 729	
enhancement area. With kind permission from Springer Science and Business Media. 730	
Figure 5. 731	
Tumor recurrence in a 32-year-old woman who underwent surgery and radiotherapy for a 732	
right temporal lobe anaplastic astrocytoma (N-acetylaspartate, NAA; choline-containing 733	
compounds, Cho; creatine, Cr). (A) The contrast-enhanced axial T1-weighted image which 734	
volume of interest for MR spectroscopy is placed on. (B) 3D proton MR spectroscopy of 735	
contrast-enhancing region in right hippocampus which shows pathologic spectra (Cho/NAA, 736	
2.91; Cho/Cr, 2.63; NAA/Cr, 0.90). (C) Photomicrograph (hematoxylin-eosin stain; original 737	
magnification, 400×) which shows a hypercellular astrocytic neoplasm. With kind permission 738	
from Springer Science and Business Media. 739	
Figure 6. 740	
An example of a target planned for a hypofractionated stereotactic radiotherapy using 741	
intensity modulated radiation therapy. (A) Contrast-enhanced T1-weighted magnetic 742	
resonance imaging. (B) 11C-methionine positron emission tomography (MET-PET). Gross 743	
tumor volume was defined as the region with high MET uptake (yellow line). The threshold 744	
for increased MET uptake was set to ≥1.3 in the contiguous tumor region. Reproduced from 745	
Radiation Oncology, Biomed Central Ltd. 746	
